(Q27851712)

English

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial (English)

1 reference

13 November 2016

0 references

phase III clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1

0 references

object named as

Angel Artal

46

0 references

Mariano Provencio

object named as

Mariano Provencio

27

0 references

Vittorio Gebbia

object named as

Vittorio Gebbia

41

0 references

Alessandra Bearz

object named as

Alessandra Bearz

45

0 references

Giuseppe Altavilla

object named as

Giuseppe Altavilla

25

0 references

Julien Mazieres

object named as

Julien Mazieres

35

0 references

object named as

Pilar Garrido

13

0 references

Enriqueta Felip

object named as

Enriqueta Felip

6

0 references

Alain Vergnenegre

4

object named as

Alain Vergnenegre

0 references

14

object named as

Flavia Longo

0 references

Enric Carcereny

2

object named as

Enric Carcereny

0 references

3

object named as

Radj Gervais

0 references

Bartomeu Massuti

5

object named as

Bartomeu Massuti

0 references

7

object named as

Ramon Palmero

0 references

Antonio Ramón Gómez-García

8

object named as

Ramon Garcia-Gomez

0 references

11

object named as

Rut Porta

0 references

Teresa Morán-López

15

object named as

Teresa Moran

0 references

16

object named as

Amelia Insa

0 references

Filippo de Marinis

17

object named as

Filippo De Marinis

0 references

18

object named as

Romain Corre

0 references

19

object named as

Isabel Bover

0 references

24

object named as

Noemi Reguart

0 references

32

object named as

Dolores Isla

0 references

Rosario Garcia-Campelo

37

object named as

Rosario Garcia-Campelo

0 references

Maria Sanchez-Ronco

49

object named as

Maria Sanchez-Ronco

0 references

Ana Drozdowskyj

50

object named as

Ana Drozdowskyj

0 references

Cristina Queralt

51

object named as

Cristina Queralt

0 references

Itziar de Aguirre

52

object named as

Itziar de Aguirre

0 references

Miguel Ángel Molina-Gutiérrez

55

object named as

Miguel Angel Molina

0 references

56

object named as

Miquel Taron

0 references

author name string

Cinta Pallares

9

0 references

Jose Miguel Sanchez

10

0 references

Manuel Cobo

12

0 references

Alfonso Illiano

20

0 references

Eric Dansin

21

0 references

Javier de Castro

22

0 references

Michele Milella

23

0 references

Ulpiano Jimenez

26

0 references

Miguel Angel Moreno

28

0 references

Josefa Terrasa

29

0 references

Jose Muñoz-Langa

30

0 references

Javier Valdivia

31

0 references

Manuel Domine

33

0 references

Olivier Molinier

34

0 references

Nathalie Baize

36

0 references

Gilles Robinet

38

0 references

Delvys Rodriguez-Abreu

39

0 references

Guillermo Lopez-Vivanco

40

0 references

Lioba Ferrera-Delgado

42

0 references

Pierre Bombaron

43

0 references

Reyes Bernabe

44

0 references

Enrico Cortesi

47

0 references

Jose Luis Ramirez

53

0 references

Jose Javier Sanchez

54

0 references

Luis Paz-Ares

57

0 references

language of work or name

0 references

publication date

March 2012

0 references

Lancet Oncology Commission

1 reference

13

0 references

239-46

0 references

3

0 references

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Implementation of group sequential logrank tests in a maximum duration trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970393-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70393-X

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851712&oldid=1860135373"